Taito Esaki

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Predictive validity of a 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) in older Japanese adults with cancer.

Predictive validity of a 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) in older Japanese adults with cancer.

Journal: Journal of the National Cancer Institute

Published: May 06, 2026

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: April 28, 2026

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Journal: Future oncology (London, England)

Published: April 15, 2026

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

Journal: JCO precision oncology

Published: March 30, 2026

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer.

Journal: iScience

Published: March 15, 2026

Comparison of sarcopenia diagnosis based on BIA-versus CT-estimated skeletal muscle mass combined with grip strength: External validation of JSH definition in older adults with cancer.

Comparison of sarcopenia diagnosis based on BIA-versus CT-estimated skeletal muscle mass combined with grip strength: External validation of JSH definition in older adults with cancer.

Journal: Clinical nutrition ESPEN

Published: February 09, 2026

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway.

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway.

Journal: ESMO open

Published: February 05, 2026

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 14, 2025

Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients.

Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients.

Journal: Journal of bone oncology

Published: September 02, 2025

Association Between Frailty and Patients' Experience of Cancer Treatment and Care.

Association Between Frailty and Patients' Experience of Cancer Treatment and Care.

Journal: Journal of the American Geriatrics Society

Published: June 17, 2025

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).

Journal: ESMO open

Published: May 27, 2025

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 16, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026